Nortriptyline
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Nortriptyline: From Depression to Attention Deficit-Hyperactivity Disorder (ADHD)
One-Sentence Summary
Nortriptyline is a tricyclic antidepressant (TCA), historically used to treat depression. The TxGNN model predicts it may be effective for Attention Deficit-Hyperactivity Disorder (ADHD), with no registered clinical trials but 20 supporting publications, including a Cochrane systematic review and several controlled studies, currently identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Depression (established indication for tricyclic antidepressants; not present in the current evidence pack) |
| Predicted New Indication | Attention Deficit-Hyperactivity Disorder (ADHD) |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L3 (systematic review and controlled studies; no registered clinical trials) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on general pharmacological knowledge, nortriptyline is a secondary-amine tricyclic antidepressant that predominantly inhibits noradrenaline reuptake (with weaker serotonergic activity), and its efficacy in depression is well established.
ADHD is understood to involve dysregulation of noradrenergic and dopaminergic signalling in the prefrontal cortex. Because nortriptyline’s principal pharmacological action is noradrenaline reuptake inhibition, a mechanistic rationale exists for activity in ADHD, and this is consistent with why TCAs (particularly desipramine and nortriptyline, the more noradrenergic agents) have historically been used as second-line, non-stimulant options for ADHD when stimulants are contraindicated or poorly tolerated — for example in patients with comorbid tic disorders.
This mechanistic plausibility is supported by decades of published clinical experience (see Literature Evidence below), although this body of evidence predates modern trial registries and current regulatory standards, and no contemporary registered clinical trials were identified.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22700161 | 2012 | RCT | Pediatric Nephrology | Randomised double-blind controlled trial of nortriptyline for enuresis in children with ADHD |
| 11052409 | 2000 | Controlled Study | J Child Adolesc Psychopharmacol | Controlled study of efficacy and tolerability of nortriptyline in paediatric ADHD |
| 25238582 | 2014 | Systematic Review (Cochrane) | Cochrane Database Syst Rev | Review of tricyclic antidepressants, including nortriptyline, for ADHD in children/adolescents |
| 7807071 | 1995 | Systematic Assessment | J Nerv Ment Dis | Systematic assessment of TCAs, including nortriptyline, in adult ADHD |
| 15064003 | 2004 | Review | Psychiatr Clin North Am | Review of non-stimulant treatments for adult ADHD; notes narrow therapeutic index/cardiovascular toxicity limiting TCA use |
| 22303520 | 2012 | Guideline/Review | Ann Clin Psychiatry | CANMAT task force recommendations for managing mood disorders with comorbid ADHD |
| 15794722 | 2005 | Review | Expert Opin Drug Saf | Safety review of non-stimulant ADHD agents, including TCAs |
| 12270803 | 2002 | Review | Adolesc Med | Overview of ADHD pharmacotherapy including tricyclic antidepressants |
| 9629412 | 1997 | Review | Arq Neuropsiquiatr | Review of drug use in ADHD, including stimulants and antidepressants |
| 8428873 | 1993 | Case Series | J Am Acad Child Adolesc Psychiatry | Nortriptyline in children with ADHD and comorbid tic disorder/Tourette’s syndrome |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: Nortriptyline is not currently marketed in the UK (0 marketing authorisations), and critical safety data (SmPC warnings, contraindications) and mechanism-of-action confirmation are both missing from the evidence pack. Although published literature — including a Cochrane review — supports a mechanistic rationale for use in ADHD, no registered clinical trials exist to substantiate this indication under current evidence standards.
To proceed, the following is needed:
- MHRA/SmPC warnings, contraindications, and drug interaction data
- Confirmed mechanism of action (DrugBank or equivalent source)
- Assessment of UK route to market (no current UK authorisation)
- Identification of any contemporary, registered clinical trials in ADHD to support the TxGNN prediction
- Paediatric cardiovascular safety data specific to ADHD populations, given known TCA cardiotoxicity concerns noted in the literature
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.